References
- Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Annals of the New York Academy of Sciences; 2016;1366(1):20–39.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–89.
- Quek AM, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012;69(8):1039–43.
- Absoud M, Lim MJ, Appleton R, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol, Neurosur Psychiatry 2015;86(4):470–2.
- Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis 2013;20(8):1086–94.
- Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010;75(12):1084–8.
- Qiu W, Wu JS, Castley A, et al. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. J Clin Neurosci 2010;17(8):1009–13.
- Yang CS, Zhang DQ, Wang JH, et al. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China. CNS Neurosci Therapeutics 2014;20(1):32–9.
- Wang J, Li X, Zhang DQ, et al. Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis. J Neuroimmunol 2015;278:26–9.
- Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84(11):1165–73.
- Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol Aging 2009;30(3):337–52.
- Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133(2):349–61.
- Chen Y, Li R, Wu AM, et al. The complement and immunoglobulin levels in NMO patients. Neurol Sci 2014;35(2):215–20.
- Nytrova P, Potlukova E, Kemlink D, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol 2014;274(1–2):185–91.
- Padovan M, Govoni M, Castellino G, et al. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int 2007;27(8):735–41.
- Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255(2):163–70.
- Lin A, Zhu J, Yao X, et al. Clinical manifestations and spinal cord magnetic resonance imaging findings in Chinese neuromyelitis optica patients. Eur Neurol 2014;71(1–2):35–41.
- Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63(3):390–6.
- Wang F, Liu Y, Duan Y, Li K. Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol 2011;80(2):445–9.